Health and life sciences - Eric Karran

Eric Karran
Director of Research Strategy
Alzheimer’s Research, UK

Eric H. Karran, PhD, is a molecular biochemist by training.  Karran is currently the director of research for Alzheimer’s Research UK, one of the largest dementia research charities in the world.  He is responsible for the organization’s strategic scientific direction. Karran is also a visiting professor in the Department for Human Genetics at the Catholic University of Leuven, Belgium; an honorary senior research associate in the Department of Molecular Neuroscience at the Institute of Neurology, University College London; and visiting professor of Neurodegenerative Diseases at the University of Lincoln, United Kingdom.

Karran launched the Drug Discovery Alliance, placing three Drug Discovery Institutes at the Universities of Oxford, Cambridge and University College London. He also launched the Dementia Consortium— a collaboration between the Medical Research Charity-Technology, Eisai Pharmaceuticals and Eli Lilly and Company— to perform validation & lead generation studies on novel targets for neurodegenerative diseases. 

Karran has spent most of his career in the pharmaceutical industry, leading and managing multi-disciplinary drug discovery teams. He has held senior positions in a number of companies, including SmithKline Beecham (now GSK), Pfizer, Eli Lilly and most recently was vice-president of Neuroscience Discovery at Johnson and Johnson. 

Karran has specialized in neuroscience research, particularly Alzheimer’s disease and cognitive impairment, for the past 20 years. During his career Karran has led teams that have put a number of drugs into clinical development.